

EX-A 14. (currently amended) A therapeutic method for preventing or treating a ~~pathological condition or symptom~~ in a mammal ~~which is associated with abnormal~~ ^{which results in progressive loss} ~~activity of a metabotropic glutamate receptor~~ of neuronal cells and/or cellular function, comprising administering to a mammal in need of such therapy, an effective amount of a compound of claim 1.

EX-A 15. (original) The method of claim 14 wherein the condition is, ~~or the symptom is~~ ^{which} ~~associated with epilepsy, cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, pain, spinal cord injury, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic damage, anxiety, neurodegenerative diseases, Huntington's Chorea, AIDS-induced dementia, ocular damage, retinopathy, cognitive disorders, Parkinson's Disease, or Multiple Sclerosis.~~

EX-A 16. (original) The method of claim 14 wherein the condition ^{which} ~~results in progressive~~ loss of neuronal cells and/or cellular function.

EX-A 17. (original) The method of claim 14 wherein the condition is, ~~or the symptom is~~ ~~associated with stroke.~~

EX-A 18. (original) The method of claim 14 wherein the condition is, ~~or the symptom is~~ ~~associated with Alzheimer's disease.~~

EX-A 19. (currently amended) A therapeutic method to treat or manage an addiction comprising administering an effective amount of a compound of claim 1 to a mammal in need of such therapy. The method of claim 14, wherein the condition or symptom is associated with morphine dependence.

EX-A 20. (currently amended) The compound of claim 1 comprising a detectable label, wherein said detectable label is selected from the group consisting of ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , and ^{18}O .